retatrutide triple hormone receptor agonist metabolic in adults with obesity over 104 weeks in the highest dose group had 30.3% weight loss. Nearly 2/3 reached BMI < 30 1 in 3 reached BMI < 25 TRIPLE HORMONE RECEPTOR AGONIST RETATRUTIDE

However, there are few studies in type 1 diabetes, so it is not clear whether this translates into increased rates of DKA." How certain side effects might impact insulin intake Anyone taking GLP-1s will likely experience a reduction in appetite, which is partly why they're so effective at weight reduction

The views expressed are those of the authors and not necessarily those of the NIHR, the UK MRC, the UK NHS or the UK Department of Health

In humans suffering from obesity, daily systemic injections of liraglutide did not ameliorate OA-related pain, probably because of poor access and hence poor local concentrations of liraglutide in the knee joint 44

We hope that clinicians are encouraged by this study to take a more comprehensive and individual approach to treatment selection, said senior author Yong Chen, PhD, a professor of Biostatistics at Penn